Materials and Methods
Cloning. The human M 5 muscarinic receptor gene (cDNA.org) was cloned into a pFastBac vector containing an N-terminal Flag epitope and a C-terminal 10x histidine tag (cDNA.org).
TEV cleavage site was introduced in order to remove the Flag epitope and the first 20 amino acids of the protein. Residues 225-430 of ICL3 were removed and replaced with T4L (SI Appendix, Fig. S1 ). In addition, to stabilize the inactive state we introduced the mutation S117 3.39 R (1, 2) . For pharmacology experiments M 2 and M 5 mAChR DNA was cloned into a pEF5/FTR/V5 vector (Invitrogen) using the Flp-In-CHO cell system (Invitrogen). To generate the M 2 /M 5 ECL chimeras overlap extension PCR was used with primers specific to each ECL region. All DNA constructs were sequenced to confirm the correct nucleotide sequence using the Australian Genome Research Facility (Melbourne, Australia).
M5 receptor expression and purification. M 5 -T4L was expressed in Sf9 cells using the Bacto-Bac Baculovirus Expression System (Invitrogen). Cells were infected at a cell density of 4.0
x 10 6 cells/millilitre with 10 µM atropine. Cells were harvested 60-72 hours later. All purification steps were performed in the presence of 1 µM triotropium. Insect cells were lysed in a buffer containing 10 mM Tris pH 7.5, 1 mM EDTA, 1 mM MgCl 2 , 1 mg/ml iodoacetamide, benzonase, and protease inhibitors. Cell membranes were then solubilised in 30 mM HEPES pH 7.4, 750 mM NaCl, 30 % glycerol, 1 % dodecyl maltoside (DDM), 0.2 % cholate, 0.03 % cholesterol hemisuccinate (CHS), 1 mM MgCl 2 , 1 mg/ml iodoacetamide, benzonase and protease inhibitors for 90 minutes at 4 o C. After removing the insoluble debris, 25 mL of Ni-NTA resin, 1 mg/ml iodoacetamide and protease inhibitors were added and incubated with the protein for 2 hours 4 o C. The Ni-NTA resin was pelleted using a table top centrifuge and then washed using 30 mM HEPES pH 7.4, 750 mM NaCl, 30 % glycerol, 5 mM imidazole pH 8.0, 0.1 % DDM, 0.02 % cholate and 0.003 % CHS. The protein was eluted using the same buffer supplemented with 250 mM imidazole. The elution was supplemented with 2 mM CaCl 2 and then loaded onto an anti-Flag M1 antibody column. The buffer/DDM was exchanged into 30 mM HEPES pH 7.4, 100 mM NaCl, 2 mM CaCl 2 , 0.1 % lauryl maltose neopentyl glycol (LMNG) and 0.01 % CHS over the course of 30 min. The resin was then washed with 10x CMC buffer (30 mM HEPES pH 7.4, 100 mM NaCl, 0.01 % LMNG and 0.001 % CHS) with 2 mM CaCl 2 before the protein was eluted using the same buffer supplemented with 10 mM EDTA and 0.2 mg/ml FLAG peptide. TEV protease was added (1mg) overnight at 4 o C before concentrating the protein for size-exclusion chromatography using a Superdex S200 increase column in 10x CMC buffer. Monodispersed fractions were pooled together (SI Appendix, Fig.   S2 ), concentrated to 80 absorbance units (~50 mg/ml) and flash frozen in small aliquots using liquid nitrogen.
Pharmacology of crystallization constructs. Sf9 cells expressing M 5 -T4L (S117R) or WT M 5 mAChR were harvested after 60 hours. Sf9 cell membranes were prepared by homogenization and centrifugation. The final membrane pellet was resuspended in 20 mM HEPES pH 7.4 and 0.1 mM EDTA. Protein concentration was determined by absorbance at 280 nm and membranes were stored at -80 o C. Assays were conducted in UniFilter-96 GF/B plates (PerkinElmer) with 1 ug of membranes per well in a final volume of 300 µl binding buffer consisting of 20 mM HEPES, 100 mM NaCl, and 10 mM MgCl 2 at pH 7.4. Non-specific binding was defined in the presence of 1 µM atropine. Assays were stopped by vacuum filtration and washed three times with ice-cold 0.9% sodium chloride. Plates were allowed to dry before 40 µL of Microscint-0 (PerkinElmer) was added to each well. Radioactivity was measured on a MicroBeta2 microplate counter. Sciences) at a concentration of 20,000 -25,000 cells per well a day before the experiment was performed in a humidified atmosphere at 37 o C, 5% CO 2 . The next day, cells were washed with assay buffer consisting of 110 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl 2 , 1 mM MgSO 4 , 25 mM glucose, 50 mM HEPES, and 58 mM sucrose, pH 7.4. Saturation binding experiments were performed similar to above with assay volumes of 150 µL. Kinetic binding dissociation experiments were performed by incubating cells with 0.2 nM [ 3 H]NMS for 3 hours at room temperature before a reverse time-course was performed. Dissociation was initiated by atropine and treatments consisted of 10 µM atropine and either vehicle, 10 µM ML375, or 10 µM 4P-C 7 /3-phth being added at the indicated time points. At the end of the time course, radioligand was removed by inverting the plate and followed by 3 washes with ice-cold 0.9% sodium chloride. Bound radioactivity was assessed by liquid scintillation using Optiphase Supermix (100 µL) and counting on a MicroBeta2 Plate Counter.
IP 1 Accumulation Assay
The IP-One assay kit (Cisbio) was used for the direct quantitative measurement of myo-inositol 1-phosphate in CHO human M 5 mAChR cells as previously described (4). Cells were seeded in 96-well plates at 25,000 cells/well the day prior to assay. On the day of the assay media was exchanged for stimulation buffer (HBSS supplemented with 10 mM HEPES, 1.3 mM CaCl 2 and 30 mM LiCl, pH 7.4) 40 min prior to stimulation with ligands. Cells were then stimulated with ligands for 40 minutes at 37°C and 5% CO 2 .
Data Analysis. Data were analysed using Prism 8.2 (GraphPad). Saturation binding curves were fitted to a one site binding curve accounting for total and non-specific binding.
Competition binding curves were fitted to a one-site binding inhibition model. Allosteric titrations between [ 3 H]NMS and modulators were fit to an allosteric ternary complex model.
Radioligand dissociation data were fitted to a mono-exponential decay function. IP 1 accumulation assays measuring the functional interaction between the NAMs and ACh were fit to a simplified operational model of allostery as previously described for the M 5 mAChR (4).
Synthesis of the bis-ammonium alkane ligands.
4B-C 7 /3-phth and 4P-C 7 /3-phth were synthesized as previously described (5) . min], 0.5 mL/min). Purity was determined by HPLC or 1 H NMR analysis and was found to be ≥95% unless stated otherwise.
Materials and Methods for Organic

General procedure A: bis-amide formation
Bis-carboxylic acid was dissolved in 1 M DCM with few drops of DMF and cooled to 0 °C.
Oxalyl chloride (2.2 eq.) was then added dropwise and the solution stirred at 0 °C for 2h. The solvent was then evaporated and the residue dissolved in THF and cooled to 0 °C. A solution of dipropyl amine (2.5 eq.) and Et 3 N (3 eq.) in THF were then added dropwise and the solution stirred at 0 °C for 30 min and for 2 h at 25 °C. After completion of reaction, 2 M HCl was added to quench the reaction and the organic layer extracted using EtOAc (×3). The combined organic layer was washed with 10% aq. Na 2 CO 3 and brine, dried with MgSO 4 and evaporated to dryness to obtain the desired product.
General procedure B: bis-amine formation
To a solution of 1.5 M THF and LiAlH 4 (2.6 eq.) at -78 °C, was slowly added bis-amide (1 eq.) dissolved in 1.5 M THF. The reaction was stirred at -78 °C for 2 h and then at 25 °C for 2 h.
After completion of reaction, 5 N NaOH was added dropwise till gas evolution ceased. The organic layer was extracted using EtOAc (×3), dried using MgSO 4 and evaporated to dryness to obtain the desired product. The compound was further purified by dissolving the crude in ether, followed by acidifying the solution using aq. 1 M HCl. The solution was washed 3 times with ether and the organic layer discarded. The aqueous layer was then basified with aq. 1 N NaOH and extracted with EtOAc (×3). The combined organic layer was then dried using MgSO 4 and evaporated to dryness.
General procedure C: bis-amine quaternarization
A mixture of bis-amine (1 eq.) and 5-bromo-2-(3-bromopropyl)isoindoline-1,3-dione (2 eq.) in ethylene carbonate (17 eq.) was taken in a sealed tube, flushed with nitrogen gas and heated to 90 °C for 60 h. Purification method A: The crude mixture was dissolved in MeOH (1 mL) and purified by preparative TLC eluting with 15% MeOH/DCM. Purification method B: The compound was purified by flash chromatography, eluting with 25-50% ethyl acetate/petroleum spirit followed by 5-7% MeOH/DCM. Purification method C: The compound was purified by preparative reversed phase HPLC to afford the product as a bis-trifluoroacetate salt.
Synthetic Methods
Scheme 1: Synthesis of 4P-C7/3-bromo-phth.
5-Bromo-2-(3-bromopropyl)isoindoline-1,3-dione
4-Bromophthalimide (500 mg, 2.21 mmol) and K 2 CO 3 (336 mg, 2.43 mmol) were dissolved in 0.8 mL of DMF. 1,3-Dibromopropane (0.67 mL, 6.64 mmol) was then added and the solution stirred at 25 °C for 12 h. After completion of reaction, the solution was evaporated and EtOAc (20 mL) was added. The solution was then washed successively with H 2 O, NH 4 Cl and brine.
The organic layer was then dried with MgSO 4 and evaporated to dryness to obtain a white solid which was recrystallized in methanol to obtain the desired product as a white solid (66%, 511 mg, 1.5 mmol). 1 H NMR (400 MHz, CDCl 3 ) δ 8.02 -7.97 (m, 1H), 7.87 (dd, J = 7.9, 1.7 Hz, 1H), 7.74 -7.69 (m, 1H), 3.84 (t, J = 6.9 Hz, 2H), 3.41 (t, J = 6.7 Hz, 2H), 2.26 (p, J = 6.7 Hz, 2H). 13 C NMR (101 MHz, CDCl 3 ) δ 167. 6, 167.0, 137.2, 133.8, 130.7, 129.2, 126.9, 124.9, 37.2, 31.6, 29.7 N 1 ,N 1 ,N 7 ,N 7 -tetrapropylheptanediamide(5) Title compound was synthesised using General procedure A using heptanedioic acid (1 g, 6.2 mmol) as a yellow oil (75%, 1.53 g). 1 19 (m, 4H), 1.74 -1.46 (m, 12H), 1.44 -1.31 (m, 2H) , 0.89 (dt, J = 14. 5, 7.4 Hz, 12H) . N 1 ,N 7 ,N 7 -tetrapropylheptane-1,7-diamine (5) Title compound was synthesised using General procedure B from N 1 ,N 1 ,N 7 ,N 7tetrapropylheptanediamide (100 mg, 0.306 mmol) as a colourless oil (49%, 45.2 mg). 1 N 1 ,N 7 -bis(3-(5-bromo-1,3-dioxoisoindolin-2-yl)propyl)-N 1 ,N 1 ,N 7 ,N 7 - tetrapropylheptane-1,7-diaminium ditriflate (4P-C 7 /3-bromo-phth) Title compound was synthesised using General procedure C from N 1 ,N 1 ,N 7 ,N 7tetrapropylheptane-1,7-diamine (150 mg, 0.5 mmol). The crude product was successively purified using methods A, B, C and B to obtain the product as a clear oil (4.3%, 22.8 mg). 1 N,N'-(1,3-phenylenebis(ethane-2,1-diyl) 
)bis(N-propylpropan-1-amine)
Title compound was synthesised using General procedure B from 2,2'- (1,3-phenylene) N,N'-(1,3-phenylenebis(ethane-2,1-diyl) )bis (3-(5- bromo-1,3-dioxoisoindolin-2-yl)-N,N- dipropylpropan-1-aminium) ditriflate (4P-aryl-C 7 /3-bromo-phth) Title compound was synthesised using General procedure C from N,N'- (1,3- phenylenebis(ethane-2,1-diyl))bis(N-propylpropan-1-amine) (76 mg, 0.23 mmol). The reaction mixture was successively purified using method B and C to obtain the product as a colourless oil (6%, 15 mg). 1 
